Lantern Pharma Inc.

LTRN

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Dec 15, 2025

Drug Pipeline

Drug Name	Phase	Indication	Designations
LP-184	Phase 2	Advanced Solid Tumor	-
LP-300	Phase 2	Adenocarcinoma of Lung	-

Catalyst Timeline

1 upcoming, 0 past

Phase 2Next

December 2025~LP-300

Primary completion for LP-300 trial (NCT05456256) in Adenocarcinoma of Lung

Regulatory Approvals

LTRN News